- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06542874
Un estudio de investigación que compara qué tan bien diferentes dosis del medicamento NNC0487-0111 reducen el azúcar en sangre en personas con diabetes tipo 2
Seguridad y eficacia de NNC0487-0111 subcutáneo una vez a la semana y oral una vez al día en participantes con diabetes tipo 2: un estudio de búsqueda de dosis
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Elsterwerda, Alemania, 04910
- Zentrum für klinische Studien Südbrandenburg GmbH
-
Elsterwerda, Alemania, 04910
- Zentrum fuer klinische Studien Suedbrandenburg GmbH
-
Essen, Alemania, 45136
- InnoDiab Forschung GmbH
-
Hamburg, Alemania, 22607
- Wendisch/Dahl Hamburg
-
Hamburg, Alemania, 22607
- Wendisch - Dahl Hamburg - DZHW
-
Münster, Alemania, 48145
- Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
-
Oldenburg in Holstein, Alemania, 23758
- RED-Institut für medizinische Forschung und Fortbildung GmbH
-
-
-
-
-
Kyustendil, Bulgaria, 2500
- Individual Practice For Specialized Outpatient Medical Care Doctor Miglena Rizova Ltd.
-
Kyustendil, Bulgaria, 2500
- IPSOMC Dr. Miglena Rizova Ltd.
-
Plovdiv, Bulgaria, 4002
- DCC Sveti Georgi EOOD
-
Plovdiv, Bulgaria, 4001
- UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases
-
Plovdiv, Bulgaria, 4002
- Diagnostic-Consultative Centre "Sveti Georgi" Eood
-
Plovdiv, Bulgaria, 4001
- UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic
-
Sofia, Bulgaria, 1431
- USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology
-
Sofia, Bulgaria, 1431
- UMHAT "Aleksandrovska"
-
Sofia, Bulgaria, 1000
- Medical centre Regina Life Clinic EOOD
-
Sofia, Bulgaria, 1431
- USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology
-
Sofia, Bulgaria, 1431
- UMHAT Aleksandrovska EAD, Densitometry and Bone Metabolic Diseases
-
Varna, Bulgaria, 9020
- AIPSMC Dr. Artin Magardichyan EOOD
-
-
-
-
-
Karlovac, Croacia, 47000
- Opca bolnica Karlovac
-
Krapinske Toplice, Croacia, 49217
- Specijalna bolnica Krapinske Toplice - Endokrinologija
-
Krapinske Toplice, Croacia, 49217
- Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology
-
Osijek, Croacia, 31 000
- Klinicki bolnicki centar Osijek_Endocrinology
-
Osijek, Croacia, 31 000
- Klinicki bolnicki centar Osijek
-
Varaždin, Croacia, 42 000
- Opca bolnica Varazdin_Endocrinology
-
Varaždin, Croacia, 42 000
- Opca bolnica Varazdin
-
-
City of Zagreb
-
Zagreb, City of Zagreb, Croacia, 10000
- Poliklinika Solmed
-
-
Primorje-Gorski Kotar County
-
Rijeka, Primorje-Gorski Kotar County, Croacia, 51 000
- KBC Rijeka, Endokrinologija
-
Rijeka, Primorje-Gorski Kotar County, Croacia, 51 000
- Clinical Hospital Centre Rijeka_Endocrinology
-
-
-
-
-
Poprad, Eslovaquia, 05801
- DENTAVIA s.r.o.
-
Prešov, Eslovaquia, 080 01
- DIABETOL, s.r.o.
-
Rimavská Sobota, Eslovaquia, 979 01
- OLIVER - MED s.r.o.
-
Žilina, Eslovaquia, 010 01
- MEDIVASA, s.r.o., Diabetologicka ambulancia
-
-
Slovak Republic
-
Šahy, Slovak Republic, Eslovaquia, 93601
- Peter Farkas MD, s.r.o.
-
-
-
-
-
A Coruña, España, 15006
- Complejo Hospitalario Universitario A Coruña
-
Barcelona, España, 08036
- Hospital Clinic i Provincial
-
Castilleja de la Cuesta, España, 41950
- Hospital Vithas Sevilla
-
Madrid, España, 28007
- Hospital Gregorio Marañón
-
Pontevedra, España
- Complejo Hospitalario de Pontevedra - Hospital de Montecelo
-
Santander, España, 39008
- Hospital Universitario Marqués de Valdecilla
-
Seville, España, 41003
- Clínica Nuevas Tecnologías en Diabetes y Endocrinología
-
Seville, España, 41010
- Hospital Infanta Luisa
-
Seville, España, 41950
- Hospital Nisa Sevilla Aljarafe
-
Seville, España, 41010
- H. Infanta Luisa_Endocrino y Obesidad
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- Uni of Alabama at Birmingham
-
-
California
-
Los Angeles, California, Estados Unidos, 90057
- Velocity Clin Research LA
-
Santa Ana, California, Estados Unidos, 92701
- Southern Cal Clinical Research
-
-
Connecticut
-
Waterbury, Connecticut, Estados Unidos, 06708
- Chase Medical Research LLC
-
-
Florida
-
Fleming Island, Florida, Estados Unidos, 32003
- Fleming Island Ctr for Clin Res
-
Hollywood, Florida, Estados Unidos, 33024
- Encore Medical Research LLC
-
Miramar, Florida, Estados Unidos, 33027
- South Broward Research LLC
-
Orlando, Florida, Estados Unidos, 32825
- Florida Inst For Clin Res
-
Orlando, Florida, Estados Unidos, 32825
- Florida Institute for Clinical research
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60607
- Cedar-Crosse Research Center
-
-
Kansas
-
Topeka, Kansas, Estados Unidos, 66606
- Cotton O'Neil Clinical Research Center
-
-
Kentucky
-
Paducah, Kentucky, Estados Unidos, 42001
- Advanced Internal Medicine, PLLC
-
-
Maryland
-
Hyattsville, Maryland, Estados Unidos, 20782
- Medstar Research Institute_Hyattsville
-
Oxon Hill, Maryland, Estados Unidos, 20745
- MD Medical Research
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Brigham & Women's Hospital
-
Methuen, Massachusetts, Estados Unidos, 01844
- ActivMed Practice & Research LLC
-
-
Michigan
-
Troy, Michigan, Estados Unidos, 48098
- Arcturus Healthcare, PLC
-
Troy, Michigan, Estados Unidos, 48098
- Arcturus HC PLC Troy Med Res
-
-
Missouri
-
Chesterfield, Missouri, Estados Unidos, 63005
- Clinical Research Professionals
-
City of Saint Peters, Missouri, Estados Unidos, 63303
- StudyMetrix Research LLC
-
-
New York
-
Albany, New York, Estados Unidos, 12203
- AMC Community Endocrinology
-
-
North Carolina
-
Morehead City, North Carolina, Estados Unidos, 28557
- Centricity Rsrch MHCity Multi
-
Statesville, North Carolina, Estados Unidos, 28625
- Piedmont Healthcare/Research
-
-
North Dakota
-
Fargo, North Dakota, Estados Unidos, 58104
- Lillestol Research LLC
-
Fargo, North Dakota, Estados Unidos, 58104
- Plains Clinical Research Center, LLC_Fargo
-
-
Oklahoma
-
Norman, Oklahoma, Estados Unidos, 73069
- Alliance for Multispec Res
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19107-6810
- Jefferson Endocrinology Assocs
-
Pittsburgh, Pennsylvania, Estados Unidos, 15236
- Preferred Primary Care Physicians_Pittsburgh
-
-
South Dakota
-
Rapid City, South Dakota, Estados Unidos, 57702
- Health Concepts
-
-
Tennessee
-
Kingsport, Tennessee, Estados Unidos, 37660
- Holston Medical Group
-
Nashville, Tennessee, Estados Unidos, 37203
- Clinical Research Associates
-
Nashville, Tennessee, Estados Unidos, 37203
- MidState Endocrine Associates
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75230
- Velocity Clinical Res-Dallas
-
Houston, Texas, Estados Unidos, 77024
- Victorium Clinical Research
-
Houston, Texas, Estados Unidos, 77079
- PlanIt Research, PLLC
-
Houston, Texas, Estados Unidos, 77061
- Synergy Groups Medical
-
Lampasas, Texas, Estados Unidos, 76550
- Radiance Clinical Research
-
McKinney, Texas, Estados Unidos, 75069
- Tekton Research
-
Waco, Texas, Estados Unidos, 76708
- Hillcrest Family Health Center
-
-
-
-
-
Athens, Grecia, 115 25
- Iatriko Psychicou Private Clinic
-
Athens, Grecia, 12462
- U.G.H of Athens "Attikon"
-
Goudi/Athens, Grecia, 11527
- "Laiko" General Hospital of Athens
-
Thessaloniki, Grecia, GR-54643
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki, Grecia, GR-57001
- "Thermi" Private Hosital
-
Thessaloniki, Grecia, 564 29
- 424 Military General Training Hospital
-
Thessaloniki, Grecia, 57001
- "Thermi" Private Hosital
-
Thessaloniki, Grecia, 54645
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki, Grecia, 564 29
- 424 Military General Training Hospital - 2nd Department of Internal Medicine
-
-
-
-
-
Budapest, Hungría, 1106
- Bajcsy-Zsilinszky Kórház
-
Budapest, Hungría, 1134
- MH Egészségügyi Központ
-
Debrecen, Hungría, 4031
- Debreceni Egyetem
-
Debrecen, Hungría, H-4031
- Debreceni Egyetem
-
Debrecen, Hungría, H-4032
- Debreceni Egyetem
-
Gyula, Hungría, 5700
- Békés Megyei Központi Kórház
-
Kaposvár, Hungría, 7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
Kaposvár, Hungría, H-7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Hungría, 4032
- Debreceni Egyetem
-
-
-
-
-
Aichi, Japón, 468-0009
- TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
-
Chiba, Japón, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Chiba, Japón, 261-0004
- Tokuyama clinic
-
Chiba-shi, Chiba, Japón, 260-0804
- Akaicho Clinic
-
Ibaraki, Japón, 311-0113
- Naka Kinen Clinic
-
Ibaraki, Japón, 311-0113
- Naka Kinen Clinic_Internal medicine
-
Tokyo, Japón, 103-0027
- Tokyo-Eki Center-building Clinic
-
Tokyo, Japón, 104-0031
- Fukuwa Clinic
-
Tokyo, Japón, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japón, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
Miyazaki
-
Miyazaki, Miyazaki, Japón, 880-0034
- Heiwadai Hospital_Internal Medicine
-
Miyazaki, Miyazaki, Japón, 880-0034
- Heiwadai Hospital
-
-
-
-
-
Bialystok, Polonia, 15-375
- Specderm Poznańska Spółka Jawna
-
Lublin, Polonia, 20-718
- EKAMED sp. z o.o.
-
Ruda Śląska, Polonia, 41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
Warsaw, Polonia, 02-507
- PANSTWOWY INSTYTUT MEDYCZNY MSWiA
-
-
Gornoslaskie
-
Ruda Śląska, Gornoslaskie, Polonia, 41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polonia, 31-261
- Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET
-
Oświęcim, Lesser Poland Voivodeship, Polonia, 32-600
- Formed 2 Sp. z o.o.
-
-
Lower Silesian Voivodeship
-
Legnica, Lower Silesian Voivodeship, Polonia, 59-220
- Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j.
-
Legnica, Lower Silesian Voivodeship, Polonia, 59-220
- Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j.
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polonia, 20-718
- EKAMED sp. z o.o.
-
-
Masovian Voivodeship
-
Siedlce, Masovian Voivodeship, Polonia, 08-110
- ETG Siedlce
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polonia, 15-879
- NZOZ Vita-Diabetica Malgorzata Buraczyk
-
Bialystok, Podlaskie Voivodeship, Polonia, 15-375
- Specderm Poznanska Sp. j.
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polonia, 90-302
- Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia
-
-
-
-
-
Brasov, Rumania, 500101
- Mariodiab Clinic SRL
-
Timișoara, Rumania, 300723
- Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara
-
Timișoara, Rumania, 300288
- Cabinet Medical Dr Geru SRL
-
-
Bihor County
-
Oradea, Bihor County, Rumania, 410025
- SC Grand Med SRL
-
Oradea, Bihor County, Rumania, 410159
- Grandmed SRL
-
-
Bucharest
-
Bucharest, Bucharest, Rumania, 020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Bucurestii
-
Bucharest, Bucurestii, Rumania, 020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Cluj
-
Cluj-Napoca, Cluj, Rumania, 400006
- Spitalul Clinic Judetean Urgenta Cluj-Napoca
-
-
Mureș County
-
Târgu Mureş, Mureș County, Rumania, 540142
- Sc Mediab Srl
-
-
Prahova
-
Ploieşti, Prahova, Rumania, 100018
- Novus Medical Clinica SRL
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female, aged 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater or equal to 180 days before screening.
- Stable daily dose(s) greater or equal to 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without SGLT2 inhibitor.
- HbA1c of 7.0-10.0 procent (53-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening.
- Body mass index between greater or equal to 23.0 and below 50.0 kg/m^2.
- Able and willing to adhere to the protocol including wearing a continuous glucose monitoring (CGM) device provided for the study, as judged by the investigator.
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Placebo subcutaneous
Placebo for subcutaneous treatment |
NNC0487-0111 placebo administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 1
NNC0487-0111 subcutaneous dose 1 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 2
NNC0487-0111 subcutaneous dose 2 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 3
NNC0487-0111 subcutaneous dose 3 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 4
NNC0487-0111 subcutaneous dose 4 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 5
NNC0487-0111 subcutaneous dose 5 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimental: NNC0487-0111 subcutaneous dose 6
NNC0487-0111 subcutaneous dose 6 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Comparador de placebos: Placebo oral
Placebo for oral treatment |
NNC0487-0111 placebo administered orally (in the mouth) |
|
Experimental: NNC0487-0111 oral dose 1
NNC0487-0111 oral dose 1 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
Experimental: NNC0487-0111 oral dose 2
NNC0487-0111 oral dose 2 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
Experimental: NNC0487-0111 oral dose 3
NNC0487-0111 oral dose 3 treatment |
NNC0487-0111 administered orally (in the mouth) |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in HbA1c
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
percent point |
From baseline (week 0) to end of treatment (week 36)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Relative change in body weight
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
percent |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
kg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
mmol/L |
From baseline (week 0) to end of treatment (week 36)
|
|
CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
percent points |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body mass index (BMI)
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
kg/m^2 |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in waist circumference
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
cm |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in average 24-hour systolic blood pressure (SBP)
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
Periodo de tiempo: From baseline (week 0) to end of study (week 40)
|
Count of events |
From baseline (week 0) to end of study (week 40)
|
|
Change in Urinary Albumin/Creatinine Ratio (UACR)
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Participant without macroalbuminuria (UACR < 300 mg/g) at baseline (week 0) developing (yes/no) new onset of macroalbuminuria (UACR ≥ 300 mg/g)
Periodo de tiempo: At end of treatment (week 36)
|
Count of participant |
At end of treatment (week 36)
|
|
Change in eGFR creatinine- and cystatin C based CKD-EPI
Periodo de tiempo: From baseline (week 0) to end of treatment (week 36)
|
mL/min/1.73 m^2 |
From baseline (week 0) to end of treatment (week 36)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Publicaciones y enlaces útiles
Publicaciones Generales
- Mora P, Aroda VR, Asong M, Bluher M, Heftdal LD, Carlander AF, Vilsen LN, Rosenstock J. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01248-1. doi: 10.1016/S0140-6736(26)01248-1. Online ahead of print.
- Mora P, Aroda VR, Asong M, Bluher M, Carlander AF, Kaltoft M, Vilsen LN, Rosenstock J. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01247-X. doi: 10.1016/S0140-6736(26)01247-X. Online ahead of print.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- NN9490-7678
- U1111-1296-9708 (Otro identificador: World Health Organization (WHO))
- 2023-509412-28 (Otro identificador: European Medical Agency (EMA))
- 2023 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .